Navigation Links
Small study shows association between medication and reduction in brain amyloid levels related to AD
Date:10/10/2011

CHICAGO -- Although it is a small study and more clinical trials are needed, treatment with the medication gantenerumab appeared to result in a reduction in brain amyloid levels in patients with Alzheimer disease, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.

"Genetic and neuropathological evidence suggests that the accumulation of amyloid-β (Aβ) peptides in the brain is a key event in the pathophysiology of Alzheimer disease (AD)," the authors provide as background information. They note that there are several therapeutic approaches currently being investigated to lower the levels of Aβ amyloid in the brain. "We previously reported the development of gantenerumab, a potent and fully human anti-Aβ antibody that binds specifically to Aβ plaques."

Susanne Ostrowitzki, M.D., from F. Hoffmann-La Roche Ltd., Neuroscience, Basel, Switzerland, and colleagues investigated whether treatment with gantenerumab leads to a measureable reduction in the level of Aβ amyloid in the brain and to try to figure out the mechanism of amyloid reduction. The study included patients with mild-to-moderate AD and was conducted at three university medical centers. Two consecutive groups of patients were randomized to receive two to seven infusions of intravenous gantenerumab (60 or 200 mg) or placebo every four weeks. Additionally, brain tissue from two patients who had AD (tissue obtained during tumor surgery) was coincubated with gantenerumab as an ex vivo study.

"Sixteen patients with end-of-treatment positron emission tomographic scans were included in the analysis," the authors report. "The mean [average] percent change from baseline difference relative to placebo (n = 4) in cortical brain amyloid level was -15.6 percent for the 60-mg group (n = 6) and -35.7 percent for the 200-mg group (n = 6)." The authors note that "Gantenerumab induced phagocytosis [a process the body uses to destroy dead or foreign cells] of human amyloid in a dose-dependent manner ex vivo."

"Our study demonstrates that two to seven months of treatment with gantenerumab led to dose-dependent amyloid reduction in the brains of patients with AD. Additionally, our findings in the placebo-treated patients support previous reports indicating that amyloid load continues to increase in many patients with mild-to-moderate AD." The authors suggest the treatment may work through an "effector cell-mediated mechanism of action."

"it is still unclear whether any reduction in brain amyloid level will translate into clinical efficacy. A phase two clinical trial is under way to investigate whether a clinical benefit can be achieved in gantenerumab-treated patients with prodromal [early symptoms] AD," the authors conclude.


'/>"/>

Contact: Luca Santarelli, M.D.
luca.santarelli@roche.com
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
2. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
3. Small Increase in Diabetes Risk Noted in Statin Patients
4. Small to Mid-Sized Hospitals Turn to Orion Health to Implement Health IT Solutions for Improved Patient Care and Outcomes
5. Media, small businesses invited to ACS Webinar on ways to take advantage of Chinas dynamic growth
6. Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program
7. Visual Cues that Improve Walking for People with Movement Disorders - Study Shows Small Change in Arrangement Can Make a Big Difference in Improvement Gained
8. Small Dogs Traced Back to Middle Eastern Wolf
9. Landrieu Comments on Presidents Small Business Health Care Report
10. Small molecule with high impact
11. A Small Grass-roots Non-profit, Announces That They Haven't Gone Away and are Still Alive with Helping the Disadvantaged Children in Ukraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... , ... In its just released 2018 Edition, The Best Lawyers in America ... third consecutive year that Hardiman and Mills have been honored and the seventh year ... Health Care Law while Mills was recognized in the Administrative and Regulatory Law category. ...
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article on NextShark ... surgery, largely influenced by the growing popularity of “pretty boys” in both K-Pop and ... standards of male appearance are changing not only in the Asian nation, where plastic ...
(Date:8/17/2017)... Valley, PA (PRWEB) , ... August 17, 2017 , ... ... Azzur Labs Ranking at No. 132 with Three-Year Sales Growth of 3,004.8% , NEW ... its 36th annual Inc. 5000, the most prestigious ranking of the nation's fastest-growing private ...
(Date:8/17/2017)... ... August 17, 2017 , ... Centrifugation is more than just ... laboratory that we can no longer do without. And just like a car, there ... device. , In this webinar, attendees will learn about the most important safety aspects ...
(Date:8/16/2017)... ... 2017 , ... Summer days spent with family are priceless. Since August is ... for enjoying the season of sunshine. Add trying something new to this summer’s bucket ... in on the fun. , Try Something New , Choose an ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: